CHARACTERIZATION OF THE INTERACTION OF THE CERVANE ALKALOID, IMPERIALINE, AT MUSCARINIC RECEPTORS INVITRO

被引:24
作者
EGLEN, RM
HARRIS, GC
COX, H
SULLIVAN, AO
STEFANICH, E
WHITING, RL
机构
[1] Institute of Pharmacology, Syntex Research, Palo Alto, California, 94304
关键词
IMPERIALINE; MUSCARINIC RECEPTOR SUBTYPES; CERVANE ALKALOIDS;
D O I
10.1007/BF00165295
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The action of the cervane alkaloid, imperialine, has been assessed at M1, M2 and M3 receptors in functional assays and at M1, M2, M3 and putative M4 sites in binding studies. In functional studies, imperialine acted as a selective surmountable antagonist at M2 receptors in guinea-pig isolated atria and uterus (-log K(B) = 7.7 and 7.4, respectively), in comparison to M1 receptors in canine isolated saphenous vein (-log K(B) = 6.9) or M3 receptors in a range of guinea-pig isolated smooth muscles including ileum, trachea, fundus, seminal vesicle or oesophagus (-log K(B) = 6.6-6.8). In rat aorta, the -log K(B) value at the M3 receptor (5.9) was slightly, but significantly, lower. In competition radioligand binding studies, imperialine was also selective toward to M2 sites in rat myocardium (-log K(i) = 7.2) with respect to M1 and M3 sites (rat cerebral cortex, rat submaxillary gland; -log K(i) = 6.1 and 5.7, respectively). However, it did not significantly discriminate between rat cardiac M2 sites and putative M4 sites in rabbit lung (-log K(i) = 6.9). Imperialine resembles the alkaloid himbacine in terms of its pharmacological profile at muscarinic receptor subtypes in that it acts as an M2 selective antagonist with respect to M1 or M3 sites. It may also provide a second, commercially available, antagonist with which to discriminate between M1 and M4 receptors.
引用
收藏
页码:144 / 151
页数:8
相关论文
共 42 条
[1]   SOME QUANTITATIVE USES OF DRUG ANTAGONISTS [J].
ARUNLAKSHANA, O ;
SCHILD, HO .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1959, 14 (01) :48-58
[3]   PHARMACOLOGY OF THE PUTATIVE M4-MUSCARINIC RECEPTOR MEDIATING CA-CURRENT INHIBITION IN NEUROBLASTOMA X GLIOMA HYBRID (NG-108-15) CELLS [J].
CAULFIELD, MP ;
BROWN, DA .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 104 (01) :39-44
[4]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[5]   [H-3]-LABELED RAUWOLSCINE AND [H-3]-LABELED YOHIMBINE BINDING TO RAT CEREBRAL AND HUMAN-PLATELET MEMBRANES - POSSIBLE HETEROGENEITY OF ALPHA-2-ADRENOCEPTORS [J].
CHEUNG, YD ;
BARNETT, DB ;
NAHORSKI, SR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1982, 84 (1-2) :79-85
[6]   ACTION OF AGONISTS AND ANTAGONISTS AT MUSCARINIC RECEPTORS PRESENT ON ILEUM AND ATRIA INVITRO [J].
CLAGUE, RU ;
EGLEN, RM ;
STRACHAN, AC ;
WHITING, RL .
BRITISH JOURNAL OF PHARMACOLOGY, 1985, 86 (01) :163-170
[7]  
COLEMAN RA, 1987, PROSTAGLANDINS RELAT, P267
[8]   STRUCTURE-ACTIVITY-RELATIONSHIPS OF SOME GALBULIMIMA ALKALOIDS RELATED TO HIMBACINE [J].
DARROCH, SA ;
TAYLOR, WC ;
CHOO, LK ;
MITCHELSON, F .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 182 (01) :131-136
[9]   AFFINITY OF MUSCARINIC RECEPTOR ANTAGONISTS FOR 3 PUTATIVE MUSCARINIC RECEPTOR-BINDING SITES [J].
DELMENDO, RE ;
MICHEL, AD ;
WHITING, RL .
BRITISH JOURNAL OF PHARMACOLOGY, 1989, 96 (02) :457-464
[10]   DIFFERENTIAL AFFINITIES OF AF-DX 116, ATROPINE AND PIRENZEPINE FOR MUSCARINIC RECEPTORS OF GUINEA-PIG GASTRIC FUNDUS, ATRIA AND URINARY-BLADDER - MIGHT ATROPINE DISTINGUISH AMONG MUSCARINIC RECEPTOR SUBTYPES [J].
DELTACCA, M ;
DANESI, R ;
BLANDIZZI, C ;
BERNARDINI, MC .
PHARMACOLOGY, 1990, 40 (05) :241-249